TSX:DND 3.71 +0.05 +1.37% Volume: 9,900 May 17, 2013
About-Us
About Us

Leadership Team

Larry Andrews , , , President and CEO

Mr. Andrews is an accomplished senior executive with more than 30 years of experience in the pharmaceutical industry. The former President of AltiMed Pharmaceuticals, Mr. Andrews is also the Founder and President of the Health Alliance Group. Mr. Andrews has played a lead role in the licensing for more than 25 compounds in the Canadian pharmaceutical market and has marketed both innovative and generic products. His career includes senior management assignments with Eli Lilly, Syntex Pharmaceuticals, and Hoffmann-La Roche.
He received his Honors BSc degree from Memorial University before joining the pharmaceutical industry.

Norman Evans , , C.A. , , Chief Financial Officer

Norman Evans has been the Chief Financial Officer since March 2007. Mr. Evans is a Chartered Accountant with more than 25 years of business experience. Prior to joining Cipher, he held the position of Vice-President, Finance at MDS Pharma Services, a division of MDS Inc. Prior to joining MDS, Mr. Evans was a Partner in the Toronto office of Ernst & Young. Mr. Evans has a Bachelor of Science degree from Concordia University in Montreal.

Jason A. Gross , , Pharm.D. , , Vice President, Scientific Affairs

Dr. Jason A. Gross has been in the pharmaceutical industry for close to 20 years. Prior to joining Cipher, he was as a Venture Partner and Vice President of Scientific Affairs at MDS Capital Corporation where he served as interim management of investee companies, coordinated and conducted scientific due diligence, and provided scientific guidance to MDS Capital's investee companies. Previously, Dr. Gross was Vice President of Regulatory Affairs and Quality Assurance for DrugAbuse Sciences and had a similar role at Zenith/Goldline Pharmaceuticals. Prior to his transition into the private sector, he was an officer in the Public Health Service assigned to the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research. He served in various regulatory capacities at the FDA, including Chief Consumer Safety Officer for the Office of Generic Drugs, Division of Bioequivalence.
Dr. Gross studied marketing and management prior to receiving his Doctor of Pharmacy from the University of Arizona, after which he completed a postdoctoral specialized residency in Ambulatory Care at the National Institutes of Health.

Joan Chypyha , , B.Sc., M.B.A. , , Vice President, Marketing and Sales

Ms. Chypyha has more than 25 years in the pharmaceutical industry with an emphasis on marketing, sales and business development. Previously Ms. Chypyha was Chief Development Officer of Rhei Pharmaceuticals Ltd.; Vice President, Corporate Development at Barrier Therapeutics Inc.; General Manager of Barrier Therapeutics Canada Inc; and Founder of Alto Pharmaceuticals Ltd. She also spent 16 years with Hoffman-La Roche in several progressively senior positions, including Business Unit Director, Dialysis and PPN and Business Unit Director, Dermatology. In this role, Ms. Chypyha was responsible for the management of a specialty sales force that represented Accutane, among other brands. Ms. Chypyha received her Bachelor of Science from University of Toronto and completed an Executive MBA from Queen’s University.